Product Overview
[Drug Name]
Generic Name: Perindopril Indapamide Tablets
Trade Name: PeiLiAn Perindopril Indapamide Tablets (4mg): 1.25mg * 21 tablets
Pinyin Full Code: PeiLiAn PeiZuoPuLiZuoDaPaAnPian (4mg): 1.25mg * 21 tablets
[Main Ingredients]
This product is a compound preparation consisting of: Perindopril tert-butylamine…4mg, Indapamide…1.25mg, and excipients suitable for one 90mg tablet.
[Properties]
This product is a white tablet.
[Indications/Main Functions]
For the treatment of essential hypertension in adults. This product is suitable for patients whose blood pressure cannot be fully controlled with perindopril alone.
[Specifications]
4mg: 1.25mg * 21 tablets
[Dosage and Administration]
Dosage: Oral dosage: Take one tablet once daily, preferably in the morning before meals. Whenever possible, gradual dose adjustment is recommended based on individual circumstances. In appropriate clinical cases, direct transition from monotherapy to levofloxacin may be considered. Patients with renal impairment (see [Precautions]). This product is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min). For patients with moderate renal impairment (creatinine clearance 30-60 mL/min), initiating treatment with an appropriate dose of a combination of drugs is recommended. No dose adjustment is required when creatinine clearance is greater than or equal to 60 mL/min. Routine medical examinations should include regular monitoring of creatinine and serum potassium levels. Patients with hepatic impairment (see [Contraindications], [Precautions], and [Pharmacokinetics]). This product is contraindicated in patients with severe hepatic impairment. No dose adjustment is required in patients with moderate hepatic impairment.
[Adverse Reactions]
See the package insert for details.
[Contraindications]
Perindopril: This product is not intended for use in the following situations: - Hypersensitivity to the active ingredient or any other ACE inhibitor; - A history of angioedema (Quincke's edema) associated with ACE inhibitor use (see Precautions); - Hereditary or idiopathic angioedema; - Pregnancy (see Precautions and Use in Pregnant and Lactating Women); - Concomitant use of Perindopril® 4 mg/1.25 mg and aliskiren-containing products in patients with diabetes or renal impairment (GFR < 60 ml/min/1.73 m²) (see Drug Interactions and Clinical Trials). - Concomitant use with sacubitril/valsartan (see Precautions and Drug Interactions). - In vitro treatments that result in contact between blood and negatively charged surfaces (see Drug Interactions). - Significant bilateral renal artery stenosis or artery stenosis of a single functioning kidney (see Precautions). Indapamide-related: This product is not intended for use in the following situations: - Hypersensitivity to the active ingredient or any other sulfonamide; - Severe renal impairment (creatinine clearance less than 30 mL/min); - Hepatic encephalopathy; - Severe hepatic impairment; - Hypokalemia. - Generally, concomitant use of this product with non-antiarrhythmic drugs that can induce torsades de pointes is not recommended (see [Drug Interactions]). - Lactation (see [Use in Pregnant and Lactating Women]). Indapamide-related: This product is not intended for use in the following situations: - Hypersensitivity to any of the excipients; Due to lack of relevant data, this product should not be used in: - Dialysis patients; - Patients with untreated decompensated heart failure.
[Precautions]
See package insert for details.
